Nanyang Technological University (LambdaGen) envisions development of next generation personalized therapeutics using its proprietary non-viral technological advance based on λ-integrase system that allows insertion of large fragments of DNA in a discrete number of non-random insertion sites which can be used to treat a wide range of diseases where a functional copy of a large disease-causing/therapeutic gene is required.
PreventAGE Health Care, led by an experienced team, is driven by the grand ambition to fundamentally improve the lives of patients with diabetes by providing biomarker-based prognostic, actionable information on their personal risk for developing specific complications (nephropathy, retinopathy, cardiovascular diseases) far in advance of any symptoms so as to preserve health and to reduce costs.
Medopad is a CE-marked patient monitoring software solution that brings together modular care monitoring tools, patient vital data tracking, and real time AI analytics to provide an easy-to-use yet holistic digital health solution.
Johnson & Johnson Innovation, JLABS (JLABS) in collaboration with Exploit Technologies Pte Ltd (ETPL) and Singapore-MIT Alliance for Research and Technology (SMART), have launched the Singapore QuickFire Challenge - Metabolic Disease Innovation to attract game-changing, early stage innovations that address this critical health concern.
Metabolic diseases such as diabetes and obesity are posing a threat to Asia Pacific like never before. Globally, over 422 million people are living with diabetes today, and about 60% of them are in Asia. The disease burden in the region continues to evolve in epidemic proportions.
Rewards and benefits
- Up to SGD100,000 in potential project money for winners*
- Access to ETPL laboratory space
- One year of mentoring and support for winners from the Johnson & Johnson Innovation, ETPL and SMART staff
- * At least one core team member of the applicant must reside in Singapore for no less than 50 percent of the term of the project.
Areas of interest
This global competition will award the person or team(s) who submits the best idea, technology, or solution focused on metabolic disease in the following areas:
- Health technologies
- Consumer healthcare
- Medical devices
Why this challenge matters to us
This Challenge aims to identify and support entrepreneur, academic, and biotech researchers with innovative ideas that have the potential of making a major difference in the lives of the millions of people in Asia Pacific and around the world who suffer from metabolic diseases such as diabetes and obesity.
Frequently Asked Questions
Each of up to three winners will be awarded SGD100,000 for research in Singapore, access to ETPL laboratory space and one year of mentorship and coaching by Johnson & Johnson Innovation, ETPL and Singapore-MIT Alliance for Research and Technology (SMART) staff.
You can apply through https://jnjawards.fluidreview.com/
We encourage applications from everyone interested in the QuickFire Challenge however, per the terms and conditions not all applicants may be eligible to win the QuickFire Challenge.
Solutions addressing metabolic disease in the Asia Pacific region in the following areas:
• Medical devices
• Consumer health
• Health technologies
All applicants must outline how the award will help them reach a critical milestone with the timeframe of a single year and provide a full “time-to-market” plan for their solution. Solutions need to meet the following criteria:
• Address a metabolic disease in the Asia Pacific region
• Integrate a novel approach within the therapeutic, device, diagnostic, consumer health and/or health technologies areas
• Address part or all of the spectrum of prevention, interception and cure
No, this is a global challenge. However, if selected as a winner or finalist, at least one core team member of the applicant company must reside in Singapore for no less than 50 percent of the term of the project.
You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.
Do not submit confidential information. Only non-confidential information should be submitted.
*For further information on eligibility for this QuickFire Challenge, please refer to the Terms & Conditions presented in your application form.
The submitted metabolic disease solutions will be evaluated based on their ability to meet the following criteria:
- Address a metabolic disease in the Asia Pacific region
- Integrate a novel approach within the therapeutic, device, diagnostic, consumer health and/or health technologies areas
- Address part or all of the spectrum of prevention, interception and cure
- Idea submission is innovative and creative
- Idea submission is scalable
- Idea submission outlines how the award would help them reach a critical milestone within the timeframe of a single year and provides a full commercialization plan.
You have to sign up for an account to get started, and you will receive an email to activate your account. You will be guided through the application process which will include signing our general Terms and Conditions Agreement, filling out your application form and uploading your non-confidential project plan.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.
About Johnson & Johnson Innovation, JLABS
Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.
JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018). For more information about JLABS, please visit www.jlabs.jnjinnovation.com.